GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (NAS:RAPT) » Definitions » Price-to-Tangible-Book

RAPT Therapeutics (RAPT Therapeutics) Price-to-Tangible-Book : 1.16 (As of May. 11, 2024)


View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics Price-to-Tangible-Book?

As of today (2024-05-11), RAPT Therapeutics's share price is $4.33. RAPT Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $3.75. Hence, RAPT Therapeutics's Price to Tangible Book Ratio of today is 1.16.

The historical rank and industry rank for RAPT Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

RAPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.15   Med: 4.12   Max: 8.24
Current: 1.15

During the past 7 years, RAPT Therapeutics's highest Price to Tangible Book Ratio was 8.24. The lowest was 1.15. And the median was 4.12.

RAPT's Price-to-Tangible-Book is ranked better than
79.77% of 1221 companies
in the Biotechnology industry
Industry Median: 2.7 vs RAPT: 1.15

A closely related ratio is called PB Ratio. As of today, RAPT Therapeutics's share price is $4.33. RAPT Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $3.75. Hence, RAPT Therapeutics's P/B Ratio of today is 1.16.


RAPT Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for RAPT Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RAPT Therapeutics Price-to-Tangible-Book Chart

RAPT Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial 8.24 4.70 5.82 2.77 5.81

RAPT Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 3.22 3.30 5.81 2.40

Competitive Comparison of RAPT Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, RAPT Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RAPT Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's Price-to-Tangible-Book falls into.



RAPT Therapeutics Price-to-Tangible-Book Calculation

RAPT Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=4.33/3.748
=1.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


RAPT Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


RAPT Therapeutics (RAPT Therapeutics) Business Description

Traded in Other Exchanges
Address
561 Eccles Avenue, South San Francisco, CA, USA, 94080
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Executives
Dirk G. Brockstedt officer: Chief Scientific Officer C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
William Ho officer: Chief Medical Officer 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendye Robbins director C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Rodney Kb Young officer: Chief Financial Officer STEMCELLS, INC., 3155 PORTER DRIVE, PALO ALTO CA 94304
Lori Lyons-williams director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Column Group Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Ii Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp 10 percent owner 1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158